July 28, 2014
Evidence is accumulating for Pfizer Japan’s anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), a treatment for non-small cell lung cancer (NSCLC) launched in May 2012, as a hopeful addition to the growing field of personalized medicine. With Chugai Pharmaceutical’s recently...read more